H.C. Wainwright Lowers PT on United Therapeutics Corporation (UTHR) to $400 From $425, Keeps a Buy Rating

United Therapeutics Corporation (NASDAQ:UTHR) is one of the top cheap pharmaceutical stocks to buy now. H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on United Therapeutics Corporation (NASDAQ:UTHR) on July 31, lowering the associated price target to $400 from $425.

Is United Therapeutics Corporation (UTHR) the Best Stock to Buy According to Jim Simons’ Renaissance Technologies?

A team of scientists in a laboratory, running tests on a biotechnology product.

The analyst based the optimistic rating on the company’s potential market opportunities and ongoing clinical trials.

He stated that the TETON trials are expected to provide notable data that may result in regulatory approval and subsequent market launch by 2027. The TETON trials are evaluating the use of nebulized Tyvaso for idiopathic pulmonary fibrosis (IPF).

Fein added that the trials are built on promising findings from the INCREASE trial, which exhibited significant improvements in lung function among IPF patients. Tyvaso also has the potential to address a considerable unmet need in the IPF market, supporting the optimistic outlook.

United Therapeutics Corporation (NASDAQ:UTHR) is a biotechnology company that develops and commercializes products for patients with chronic and life-threatening conditions. Its product portfolio includes Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin.

While we acknowledge the potential of UTHR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than UTHR and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.